公开(公告)号：EP4321538A1

公开(公告)日：2024-02-14

申请号：EP22775781.2

申请日：2022-03-24

申请人： The University of Tokyo ,  Savid Therapeutics Inc.

发明人： TANAKA Toshiya ,  KODAMA Tatsuhiko ,  KANAI Motomu ,  YAMATSUGU Kenzo ,  TATSUMI Toshifumi ,  TAKAHASHI Kazuki ,  SUGIYAMA Akira ,  TSUKAGOSHI Masanobu

IPC分类号： C07K19/00 ,  A61K31/695 ,  A61K38/16 ,  A61K39/395 ,  A61K41/00 ,  A61K45/00 ,  A61K47/54 ,  A61K47/66 ,  A61K47/68 ,  A61K49/00 ,  A61P35/00 ,  C07K4/00 ,  C07K14/00 ,  C07K14/36 ,  C07K16/28 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/11 ,  C12N15/13

摘要： It is an object of the present invention to provide a fusion protein of a molecule that recognizes cancer cells or the like and a mutant streptavidin, wherein the fusion protein is for use in the treatment or diagnosis of a cancer. According to the present invention, provided is a fusion protein, wherein an antigen-binding molecule having a molecular weight of 20,000 or less is bound, via a linker sequence, to the N-terminal side and/or C-terminal side of the amino acid sequence as set forth in SEQ ID NO: 1, provided that the C-terminal amino acid sequence consisting of Pro-Ser-Ala-Ala-Ser His-His-His-His-His-His may be partially or entirely deleted.

公开(公告)号：EP3903790A1

公开(公告)日：2021-11-03

申请号：EP19902517.2

申请日：2019-12-27

申请人： The University of Tokyo ,  Savid Therapeutics Inc.

发明人： TANAKA Toshiya ,  KODAMA Tatsuhiko ,  YAMASHITA Takefumi ,  KANAI Motomu ,  YAMATSUGU Kenzo ,  TATSUMI Toshifumi ,  TAKAHASHI Kazuki ,  ISHIKAWA Shumpei ,  SUGIYAMA Akira ,  TSUKAGOSHI Masanobu

IPC分类号： A61K31/695 ,  A61P35/00 ,  C07K16/30 ,  C07K19/00 ,  A61K47/42 ,  A61K47/54 ,  C12N15/13 ,  C12N15/31 ,  C12N15/62 ,  G01N33/531 ,  G01N33/574

摘要： It is an object of the present invention to provide a fusion protein of an antibody that recognizes cancer cells and a mutant streptavidin, which is for use in the treatment or diagnosis of cancer. According to the present invention, provided is a fusion protein having the amino acid sequence as set forth in SEQ ID NO: 2 or SEQ ID NO: 7, a linker sequence, and the amino acid sequence as set forth in SEQ ID NO: 1 (provided that the amino acid sequence portion consisting of 6 histidine residues at the C-terminus thereof may be partially or entirely deleted), from the N-terminal side to the C-terminal side, in this order.

公开(公告)号：EP3834845A1

公开(公告)日：2021-06-16

申请号：EP19846407.5

申请日：2019-08-08

申请人： The University of Tokyo ,  Savid Therapeutics Inc.

发明人： KANAI Motomu ,  YAMATSUGU Kenzo ,  TATSUMI Toshifumi ,  TAKAHASHI Kazuki ,  KODAMA Tatsuhiko ,  TANAKA Toshiya ,  YAMASHITA Takefumi ,  SUGIYAMA Akira ,  TSUKAGOSHI Masanobu

IPC分类号： A61K47/54 ,  A61K31/695 ,  A61K41/00 ,  A61P35/00 ,  C07K14/36 ,  C07K16/22 ,  C07K16/30 ,  C07K16/32 ,  C07K19/00 ,  C09B47/18 ,  C12N15/76

摘要： It is an object of the present invention to provide a conjugate of a biotin-modified dimer and a phthalocyanine dye, which is used in photoimmunotherapy. The present invention provides a conjugate of a compound represented by the following formula (1) or a salt thereof and a phthalocyanine dye:

wherein the meaning of each of symbols is as defined in the specification.

公开(公告)号：EP4101506A1

公开(公告)日：2022-12-14

申请号：EP21750642.7

申请日：2021-02-04

申请人： The University of Tokyo ,  Savid Therapeutics Inc.

发明人： KANAI Motomu ,  YAMATSUGU Kenzo ,  TATSUMI Toshifumi ,  TAKAHASHI Kazuki ,  KODAMA Tatsuhiko ,  SUGIYAMA Akira ,  TSUKAGOSHI Masanobu ,  TODA Yuzo

IPC分类号： A61P35/00 ,  C09B47/30 ,  C07K16/28 ,  C07F7/10 ,  C07D487/22 ,  A61K47/55 ,  A61K47/64 ,  A61K47/68 ,  A61K41/00 ,  A61K31/695

摘要： Objects of the present invention are to provide a novel phthalocyanine dye for use in photoimmunotherapy, and a method for producing the same, and to provide a conjugate of the above-described phthalocyanine dye and an antibody or a peptide. According to the present invention, a compound represented by the following formula (1) or a salt thereof is provided:

wherein X represents a substituent having a hydrophilic group at the terminus thereof; L 3 , L 4 , L 5 , and L 6 each independently represent a divalent linking group; Y represents a group capable of binding to an antibody or a peptide; R 3 represents a substituent, such as an alkyl group containing 1 to 6 carbon atoms, an alkoxy group containing 1 to 6 carbon atoms, a halogen atom, -SR 11 , -SOR 12 , an aryl group containing 6 to 10 carbon atoms, -N(R 13 )(R 14 ), or -NO 2 , wherein when a plurality of R 3 s are present, the plurality of R 3 s may be identical to or different from one another; and s represents an integer of 0 to 4.